Astellas Transfers Three European Plants to Temmler Group, German Pharmaceutical Company.Tokyo Tokyo (tō`kēō), city (1990 pop. 8,163,573), capital of Japan and of Tokyo prefecture, E central Honshu, at the head of Tokyo Bay. , Japan, Dec 21, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) Newswire) - Astellas Pharma Astellas Pharma Inc. (アステラス製薬株式会社 Inc. (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : 4503) today announced that Temmler Group, German pharmaceutical company and Astellas have reached an agreement and concluded a contract providing for the transfer by Astellas of bulk assets comprising the Munich Munich (my  `nĭk), Ger. München (mün`khən), city (1994 pop. 1,255,623), capital of Bavaria, S Germany, on the Isar River near the Bavarian Alps. Plant and Klinge Klinge (Lower Sorbian: Glinka) is a village in the Lausitz, east of the city of Cottbus in Brandenburg.The Bahnhof Klinge is served once an hour in each direction by the RB46 train travelling between Cottbus and Forst. External link A train at Bahnhof Klinge Ireland Ireland, Irish Eire (âr`ə) [to it are related the poetic Erin and perhaps the Latin Hibernia], island, 32,598 sq mi (84,429 sq km), second largest of the British Isles. Plant of Astellas Deutschland GmbH, and all stocks of Produzioni Farmaceutiche Carugate S.r.l, to Temmler Group. Astellas has previously declared in its mid-term 5-year management plan, ending in FY2010 (fiscal year ending March 2011), that the number of production sites will be reduced from the current 18 ( 9 in Japan and 9 overseas) to around 10 by FY2010 to achieve an optimal production system. This transfer of three plants has been effected in order to carry out this mid-term 5-year management plan. Temmler Group is a German company engaged in the manufacturing, sales, and contract manufacturing of pharmaceuticals with extensive experience in Europe. Approximately 400 employees will be transferred to Temmler Group. The products which are currently manufactured at the plants will be sourced from Temmler Group. The transfer of three plants concerned is planned for January 1, 2007. Astellas is planning on accounting the special losses of 4.6 billion yen as streamlining cost of three European European emanating from or pertaining to Europe. European bat lyssavirus see lyssavirus. European beech tree fagussylvaticus. European blastomycosis see cryptococcosis. production sites in earning forecast of the fiscal year ending March 2007. However, the slight increase in the final amount is expected. About Astellas Pharma Inc. Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. In April 2005, the company was formed through the merger of Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. The organization is committed to becoming a global mega pharmaceutical company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. For more information on Astellas Pharma Inc., please visit the company's website at www.astellas.com. Source: Astellas Pharma Inc. Contact: Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com Copyright [c] 2006 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion